SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the BIOCOM Investor Conference on
Thursday, November 1, 2007 at 9:30 a.m. PT in San Diego. Daniel M.
Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals,
will be providing a corporate overview.
The live presentation will be webcast, and a recording will be made
available following the event. The webcast and recording will be accessible
through Amylin's corporate website, located at http://www.amylin.com. To
access the live webcast, please log on to Amylin's site approximately
fifteen minutes prior to the presentation to register and download any
necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed
to improving lives through the discovery, development and commercialization
of innovative medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
located in San Diego, California with over 1,800 employees nationwide.
Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com
CONTACT:
Alice Bahner Izzo, Executive Director of
Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, x7272
|
